Biological E gets nod to conduct late-stage clinical trials of its COVID-19 vaccine

The Phase III clinical study, which is to be conducted in 15 sites across India, will evaluate the Immunogenicity and Safety of Biological E’s SARS-CoV-2 COVID-19 vaccine for protection against COVID-19 disease in about 1,268 healthy subjects in the age range of 18 to 80 years. It is intended to be part of a larger global Phase III study.

from Moneycontrol Business News https://ift.tt/3njGa3e